Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 451

1.

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.

Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulias V.

PLoS One. 2015 Jun 17;10(6):e0123683. doi: 10.1371/journal.pone.0123683. eCollection 2015.

2.

Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.

Koinis F, Nintos G, Georgoulias V, Kotsakis A.

Expert Opin Pharmacother. 2015 Jul;16(10):1505-19. doi: 10.1517/14656566.2015.1055248. Epub 2015 Jun 16.

PMID:
26077189
3.

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).

O'Brien ME, Gaafar R, Hasan B, Menis J, Cufer T, Popat S, Woll PJ, Surmont V, Georgoulias V, Montes A, Blackhall F, Hennig I, Schmid-Bindert G, Baas P; EORTC-LCG.

Eur J Cancer. 2015 Jun 11. pii: S0959-8049(15)00388-3. doi: 10.1016/j.ejca.2015.04.026. [Epub ahead of print]

PMID:
26074395
4.

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.

Polioudaki H, Agelaki S, Chiotaki R, Politaki E, Mavroudis D, Matikas A, Georgoulias V, Theodoropoulos PA.

BMC Cancer. 2015 May 13;15:399. doi: 10.1186/s12885-015-1386-7.

5.

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece.

Ann Oncol. 2015 Jul;26(7):1333-40. doi: 10.1093/annonc/mdv213. Epub 2015 May 1.

6.

The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer.

Matikas A, Asimakopoulou N, Georgoulias V, Souglakos J.

Cancers (Basel). 2015 Mar 13;7(1):439-49. doi: 10.3390/cancers7010439. Review.

7.

A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples.

Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Chim Acta. 2015 Apr 15;444:303-9. doi: 10.1016/j.cca.2015.02.035. Epub 2015 Feb 27.

PMID:
25727515
8.

Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2015 Apr;75(4):821-7. doi: 10.1007/s00280-015-2707-x. Epub 2015 Feb 22.

PMID:
25702051
9.

Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs.

Matikas A, Mistriotis D, Georgoulias V, Kotsakis A.

Clin Lung Cancer. 2015 Jul;16(4):252-261. doi: 10.1016/j.cllc.2014.12.013. Epub 2015 Jan 8. Review.

PMID:
25700775
10.

Metastasis-related miRNAs: a new way to differentiate patients with higher risk?

Markou A, Lianidou E, Georgoulias V.

Future Oncol. 2015;11(3):365-7. doi: 10.2217/fon.14.294. No abstract available.

11.

Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).

Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V.

Lung Cancer. 2015 Apr;88(1):57-62. doi: 10.1016/j.lungcan.2015.01.012. Epub 2015 Jan 23.

PMID:
25662596
12.

ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, Xyrafas A, Kotsakis A, Agelaki S, Souglakos J, Mavroudis D, Georgoulias V.

Cancer Invest. 2015 Apr;33(4):107-13. doi: 10.3109/07357907.2014.1001897. Epub 2015 Feb 3.

PMID:
25647444
13.

A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.

Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, Mavroudis D, Georgoulias V, Kotsakis A.

J Immunol Res. 2014;2014:659294. doi: 10.1155/2014/659294. Epub 2014 Nov 11.

14.

Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.

Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F, Kalbakis K, Georgoulias V, Agelaki S.

Breast Cancer Res. 2014 Nov 29;16(6):485. doi: 10.1186/s13058-014-0485-8.

15.

Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).

Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulias V, Mavroudis D.

Breast Cancer Res Treat. 2014 Dec;148(3):591-7. doi: 10.1007/s10549-014-3202-5. Epub 2014 Nov 16.

PMID:
25399229
16.

PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.

Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Cancer Res. 2014 Nov 15;20(22):5823-34. doi: 10.1158/1078-0432.CCR-14-0149.

PMID:
25398847
17.

Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.

Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60. doi: 10.1007/s00280-014-2628-0. Epub 2014 Nov 15.

PMID:
25398698
18.

Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.

Georgoulias V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, Mavroudis D.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1217-25. doi: 10.1007/s00280-014-2598-2. Epub 2014 Oct 26.

PMID:
25344760
19.

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.

Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, Voutsina A, Koutsopoulos A, Mavroudis D, Georgoulias V, Souglakos J.

Br J Cancer. 2014 Oct 28;111(9):1757-64. doi: 10.1038/bjc.2014.492. Epub 2014 Sep 18.

PMID:
25233397
20.

The optimum duration of front-line chemotherapy.

Kotsakis A, Georgoulias V.

Lancet Oncol. 2014 Oct;15(11):1187-8. doi: 10.1016/S1470-2045(14)70434-6. Epub 2014 Sep 14. No abstract available.

PMID:
25232000
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk